Traditional Chinese medicine composition for treating obesity and application

Abstract

The invention discloses a traditional Chinese medicine composition for treating obesity and application. The traditional Chinese medicine composition is prepared from 4-8 parts of pericarpium citri reticulatae, 4-8 parts of fructus mume, 8-12 parts of dendrobe, 8-12 parts of white hyacinth bean, 13-17 parts of malt, 4-8 parts of hawthorn, 13-17 parts of microcos paniculata and 1-5 parts of stevia rebaudiana. The traditional Chinese medicine composition has the following advantages: the traditional Chinese medicine composition has a good curative effect on dyslipidemia and impaired glucose tolerance caused by obesity, especially abnormal fat metabolism, and can obviously improve clinical symptoms of obese patients; the traditional Chinese medicine composition has the effects of tonifying spleen and reducing fat, has no obvious damage to liver functions, and has a protective effect, so that the safety is relatively high. Therefore, the traditional Chinese medicine composition can be used for treating obesity.

Description

Technical Field

[0001] The invention relates to a Chinese medicine composition solid beverage, in particular to a Chinese medicine composition for treating obesity and its application. Background Art

[0002] Obesity is a chronic, recurrent and progressive disease. According to the 2024 World Obesity Report, there are 2.2 billion overweight or obese adults in 2020, accounting for 42% of the global population, and this proportion will exceed 54% in 2035. A cross-sectional real-world study of 15.8 million adults published in my country in 2023 showed that 34.8% of people were overweight and 14.1% were obese. According to the latest estimates of the "Global Burden of Disease Study 2024", 42 million deaths and 1.6 billion disability-adjusted life years are caused by four non-communicable diseases each year: cancer, coronary heart disease, stroke and diabetes. Each of the above diseases is related to and aggravated by overweight and obesity, and obesity has become a global public health challenge. In addition to low-calorie diets and increased physical activity, long-term weight management can be supplemented with drug therapy. Clinical applications have shown that long-term use of weight loss drugs is necessary in long-term weight management. However, most of the drugs currently approved by the FDA have contraindications and adverse reactions, and their drug safety is worrying during the long period of use. For example, many studies have reported some side effects associated with conventional treatments: gastrointestinal diseases caused by injections of glucagon-like peptide analogs, and frequent gastrointestinal reactions caused by taking gastrointestinal lipase inhibitors. Striving to find safe weight loss methods and drugs is still a medical problem in the world today. Summary of the invention

[0003] The primary purpose of the present invention is to overcome the shortcomings and deficiencies of the prior art and provide a Chinese medicine composition for treating obesity.

[0004] Another object of the present invention is to provide an application of the above-mentioned traditional Chinese medicine composition for treating obesity.

[0005] The object of the present invention is achieved by the following technical scheme: a Chinese medicine composition for treating obesity, comprising the following ingredients in parts by mass: 4-8 parts of dried tangerine peel, 4-8 parts of ebony, 8-12 parts of dendrobium, 8-12 parts of white hyacinth bean, 13-17 parts of malt, 4-8 parts of hawthorn, 13-17 parts of buza leaves, and 1-5 parts of stevia; preferably comprising the following ingredients in parts by mass: 5-7 parts of dried tangerine peel, 5-7 parts of ebony, 9-11 parts of dendrobium, 9-11 parts of white hyacinth bean, 14-16 parts of malt, 5-7 parts of hawthorn, 14-16 parts of buza leaves, and 2-4 parts of stevia; more preferably comprising the following ingredients in parts by mass: 6 parts of dried tangerine peel, 6 parts of ebony, 10 parts of dendrobium, 10 parts of white hyacinth bean, 15 parts of malt, 6 parts of hawthorn, 15 parts of buza leaves, and 3 parts of stevia.

[0006] The obesity is preferably simple obesity.

[0007] The malt is preferably roasted malt.

[0008] Application of the traditional Chinese medicine composition for treating obesity in preparing a preparation for treating obesity.

[0009] A preparation for treating obesity is prepared by the following steps: extracting the above-mentioned Chinese medicine composition for treating obesity, and preparing the obtained extract into a desired dosage form.

[0010] The extraction includes water extraction and supercritical extraction.

[0011] The water extraction step is preferably as follows: soaking the above-mentioned traditional Chinese medicine composition for treating obesity with water, followed by decocting, solid-liquid separation, obtaining a medicinal solution and a medicinal residue, repeatedly decocting the medicinal residue for more than 0 times, combining the obtained medicinal solutions, and obtaining an extract. The repeated decoction is for better extracting the effective ingredients of the above-mentioned traditional Chinese medicine composition for treating obesity.

[0012] The amount of water is preferably calculated according to the ratio of the above-mentioned Chinese medicine composition for treating obesity: water = solid-liquid ratio of 1:2 to 1:15 (g:mL); more preferably calculated according to the above-mentioned Chinese medicine composition for treating obesity: water = solid-liquid ratio of 1:2 to 4 (g:mL).

[0013] The decoction time is preferably 30 to 60 minutes, and more preferably 30 to 40 minutes.

[0014] The amount of water used in the repeated decoction is preferably calculated according to the ratio of the above-mentioned Chinese medicine composition for treating obesity: water = solid-liquid ratio of 1:2 to 1:15 (g:mL); more preferably calculated according to the above-mentioned Chinese medicine composition for treating obesity: water = solid-liquid ratio of 1:2 to 4 (g:mL).

[0015] The repeated decoction time is preferably 30 to 60 minutes, and more preferably 30 to 40 minutes.

[0016] The number of repeated decoctions is preferably 1 to 3 times, and more preferably 2 times.

[0017] The dosage form is preferably decoction, pill, powder, paste, pill, granule, oral liquid, capsule, tablet, injection.

[0018] The preparations include common preparations, sustained-release preparations, controlled-release preparations, targeted preparations and microparticle drug delivery systems.

[0019] The obesity is preferably simple obesity.

[0020] The method for using the above-mentioned preparation for treating obesity includes the following steps: taking the medicine twice a day, taking it again after six hours after the first dose, and exercising appropriately one hour after taking the medicine, preferably with slight sweating.

[0021] So far, the treatment of obese patients includes oral slimming drugs (orlistat) and semaglutide injection, lidoglutide injection, monotherapy and combination therapy, and all kinds of obese people need to take medicine every day. However, the safety of various slimming drugs for long-term use is worrying, especially the gastrointestinal reaction is more obvious. The present invention aims to expand the unique advantages of traditional Chinese medicine in obesity treatment from the aspects of lipid reduction, low side effects, and high safety for long-term use. Traditional Chinese medicine believes that the pathogenesis of obesity is generally due to the deficiency of yang qi and excess phlegm and dampness, and the main location of the disease is the spleen and stomach. When the transportation and transformation function of the spleen and stomach is unbalanced, problems with water metabolism occur, which in turn form phlegm and dampness, and the blockage of phlegm and dampness can lead to obesity. The inventor believes that the pathogenic factors of modern obesity are mostly caused by the exposure to external pathogens, internal heat, and phlegm and dampness, blood stasis, emotional injury caused by eating too much fat, sweet and greasy food, being relaxed and less active, and excessive worry, which leads to internal disorder of qi, dietary discomfort, and spleen and stomach disorders; or due to physical deficiency, it is impossible to expel the pathogens, and the deficiency is caused by the fullness, and each exposure to external pathogens causes imbalance of the body, which leads to obesity. According to the above pathogenesis, the inventor innovatively established the treatment method of "expelling phlegm and dampness, strengthening the spleen and digesting food" and created the tangerine peel spleen-strengthening and phlegm-removing prescription, which is composed of 4-8 parts of tangerine peel, 4-8 parts of black plum, 8-12 parts of dendrobium, 8-12 parts of white hyacinth bean, 13-17 parts of malt, 4-8 parts of hawthorn, 13-17 parts of slag leaves, and 1-5 parts of stevia. The amount of tangerine peel in this prescription plays an important role in promoting qi circulation, strengthening the spleen, and removing phlegm, so it is identified as the main medicine. It is combined with other medicines to jointly exert the effects of removing phlegm and dampness and strengthening the spleen and digestion.

[0022] The symptoms of "three mores and one less" in modern obese patients are often not obvious, because the vital energy has not yet been obviously deficient, and the four evils of phlegm, heat, wind, and fluid invade the human body but do not cause disease immediately, but lurk in the meridians, internal organs (mostly in the lungs, spleen, and kidneys). In this prescription, tangerine peel enters the lung and spleen meridians, clears and nourishes the lung yin, and is suitable for the syndrome of mild damage to the lung yin and lurking evils. By nourishing the lungs, the function of dispersing and descending is restored, and the lung meridian is unobstructed, and the evils have nowhere to hide; the lung governs the skin and fur, and can also make the hidden evils be resolved. At the same time, it has the effect of benefiting the stomach and producing body fluids, restoring the acquired spleen and stomach transportation and transformation functions, and eliminating the source of phlegm and fluid production, thereby exerting the effect of strengthening the foundation to clear the source, strengthening the spleen and digesting food. Dendrobium can invigorate Qi and strengthen the spleen, promote diuresis and calm the mind. When combined with dried tangerine peel, it can better restore the function of spleen and stomach transportation and transformation, and at the same time, it is good at removing moisture from the body, and can play the role of eliminating hidden drink by strengthening the foundation and clearing the source; white hyacinth bean belongs to the three meridians of lung, spleen and kidney, and can open the meridians and enter the collaterals, and can deeply search and pick out the hidden wind that penetrates into the collaterals. Phlegm and heat are the two most likely factors (inducing factors) for obesity to induce hidden evil and cause many symptoms. In the prescription, black plum can purge fire and detoxify, clear heat and dry dampness, and is good at benefiting dampness and heat in the middle jiao, which can eliminate the factors of hidden heat. Wind is the leader of all diseases, and it often enters the collaterals with dampness, heat and other evil qi. Hyacinth bean is good at expelling wind, drink and heat evil, which can make the three evils disappear and expel them. At the same time, it is combined with dried tangerine peel to thoroughly resolve hidden evil. The reconciliation method is one of the important treatment principles for hidden evil. Malt and stevia are sweet and warm to open the collaterals, harmonize the Ying and Wei, and are good at regulating the limbs, and together play the role of regulating and resolving hidden wind, hidden phlegm, hidden drink and hidden heat. Hawthorn and Buza leaves can clear away heat and remove phlegm, strengthen the spleen and digest food, moisten the lungs and relieve cough, and can eliminate the causes of hidden phlegm. The eight herbs work together to consolidate the foundation, clear the source, remove phlegm and eliminate dampness, so as to play the role of clearing and nourishing the lungs, spleen and kidneys, reconciling and penetrating hidden evil, and eliminating the causes of hidden evil. At the same time, an obese mouse model was constructed by feeding with a high-fat diet to investigate the therapeutic effects of this prescription and the proposed prescription on obesity. The experimental results show that this group of prescriptions can effectively reduce the weight and fat content of mice fed with high-fat diets, reduce the blood lipid level of obese mice, and improve fatty liver lesions in obesity.

[0023] Compared with the prior art, the present invention has the following advantages and effects:

[0024] (1) The inventors have discovered for the first time that the Chenpi Jianpi Qutan Decoction has a good therapeutic effect on dyslipidemia, impaired glucose tolerance, and especially abnormal fat metabolism caused by obesity, and can significantly improve the clinical symptoms of obese patients.

[0025] (2) The tangerine peel invigorating spleen and eliminating phlegm prescription provided by the present invention has the effects of invigorating the spleen and eliminating fat, has no obvious damage to liver function, and has a protective effect, so it is relatively safe.

[0026] (3) The tangerine peel invigorating spleen and removing phlegm prescription provided by the present invention mainly uses medicinal flavors that are both medicinal and edible, and tangerine peel itself has the effect of regulating qi and strengthening the spleen. Compared with Western medicine weight loss drugs (such as semaglutide, orlistat, etc.), it has lower gastrointestinal adverse reactions and can be taken for a long time, and has broad application prospects in the field of obesity treatment.

[0027] (4) Compared with other proposed prescriptions, the tangerine peel weight-loss prescription provided by the present invention has better effects and is more effective in obesity treatment and effect maintenance.

[0028] (5) The preparation method provided by the present invention is prepared by decocting the raw materials with water, which has the advantages of being adaptable to TCM syndrome differentiation and treatment, adding or subtracting according to symptoms, being rapidly absorbed, having a strong effect and being long-lasting. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 This is the body weight result of each group of mice at week 12 after drug intervention; among them, ** indicates p<0.01 compared with the model group; *** indicates p<0.001 compared with the model group; *** indicates p<0.01 compared with the model group.

[0030] Figure 2 The graph is the cholesterol (TC) level result of each group of mice at 12 weeks after drug intervention; among them, * indicates p < 0.05 compared with the model group, ** indicates p < 0.01 compared with the model group, *** indicates p < 0.01 compared with the model group.

[0031] Figure 3 The figure is the result of low-density lipoprotein (LDL-C) level of each group of mice at 12 weeks after drug intervention; among them, * indicates p < 0.05 compared with the model group, ** indicates p < 0.01 compared with the model group, *** indicates p < 0.01 compared with the model group.

[0032] Figure 4 The results of alanine aminotransferase (ALT) levels in each group of mice at week 12 after drug intervention; among them, * indicates p < 0.05 compared with the model group, ** indicates p < 0.01 compared with the model group, and *** indicates p < 0.01 compared with the model group.

[0033] Figure 5 The results of aspartate aminotransferase (AST) levels in mice of each group at week 12 after drug intervention; among them, * indicates p < 0.05 compared with the model group, ** indicates p < 0.01 compared with the model group, *** indicates p < 0.01 compared with the model group.

[0034] Figure 6 The figure is the result of creatinine (Cr) level of each group of mice at week 12 after drug intervention; among them, * indicates p < 0.05 compared with the model group, ** indicates p < 0.01 compared with the model group, *** indicates p < 0.01 compared with the model group.

[0035] Figure 7The results of the urea nitrogen (BUN) level of each group of mice at week 12 after drug intervention; among them, * indicates p < 0.05 compared with the model group, ** indicates p < 0.01 compared with the model group, and *** indicates p < 0.01 compared with the model group.

[0036] Figure 8 The white fat content of each group of mice at 12 weeks after drug intervention; among them, * indicates p<0.05 compared with the model group, ** indicates p<0.01 compared with the model group, and *** indicates p<0.01 compared with the model group.

[0037] Fig. 9 The white fat index diagram of each group of mice at 12 weeks after drug intervention; among them, * indicates p<0.05 compared with the model group, ** indicates p<0.01 compared with the model group, and *** indicates p<0.01 compared with the model group.

[0038] Fig.10 This is the HE staining morphology of the liver of each group of mice at week 12 after drug intervention.

[0039] Fig.11 The NAFLD score chart of each group of mice at week 12 after drug intervention; among them, * indicates p<0.05 compared with the model group, ** indicates p<0.01 compared with the model group, and *** indicates p<0.01 compared with the model group.

[0040] Fig.12 This is the HE staining morphology of epididymal white fat in each group of mice at 12 weeks after drug intervention.

[0041] Fig.13 The figure is a statistical chart of epididymal white fat diameters of mice in each group at week 12 after drug intervention; among them, * indicates p < 0.05 compared with the model group, ** indicates p < 0.01 compared with the model group, and *** indicates p < 0.01 compared with the model group. DETAILED DESCRIPTION

[0042] The present invention is further described in detail below in conjunction with embodiments and drawings, but the embodiments of the present invention are not limited thereto.

[0043] Example 1 Experimental study on the efficacy of the Tangerine Peel Invigorating the Spleen and Eliminating Phlegm Recipe in preventing obesity in mice induced by a high-fat diet

[0044] The obesity model fed with high-fat diet is a classic obesity model, which is characterized by simplicity, easy film formation, high fat content, and stable body weight gain. Its main symptoms are high body weight, high fat content, and metabolic disorders, which are similar to the etiology and pathological process of human obesity. Therefore, the obesity model induced by high-fat diet can be used as an experimental obesity model. In this example, the obesity induced by high-fat diet is used as an experimental disease model to explore whether the Chenpi Jianpi Qutan Decoction can delay the progression of obesity and evaluate the weight loss effect of the Chenpi Jianpi Qutan Decoction through formula design and dose-effect relationship.

[0045] 1. Experimental materials

[0046] (1) Experimental animals

[0047] Forty-eight clean-grade male C57BL / 6J mice, weighing 18±4 g, were purchased from Zhuhai Besttone Biotechnology Co., Ltd. (License number: SCXK(Yue)2020-0051). After 1 week of adaptive feeding, they were fed with a high-fat diet (D124912) for 12 weeks, and gavage administration was started at the same time. The experimental mice were housed in the barrier environment of the Animal Experiment Center of Guangzhou University of Chinese Medicine, and the experimental operation procedures were carried out according to the guidelines formulated by the Animal Experiment Center of Guangzhou University of Chinese Medicine.

[0048] (2) Drug grouping

[0049] According to the source of the prescription, Group A without the monarch drug "Chenpi" (7 g of Fructus Mume, 11 g of Herba Dendrobii, 11 g of Semen Lablab Album, 16 g of Fructus Hordei Germinatus, 7 g of Fructus Crataegi, 16 g of Folium Microcos, 3 g of Stevia rebaudiana) was formulated, Group B without the ministerial drug "Herba Dendrobii" (8 g of Chenpi, 8 g of Fructus Mume, 12 g of Semen Lablab Album, 16 g of Fructus Hordei Germinatus, 7 g of Fructus Crataegi, 16 g of Folium Microcos, 4 g of Stevia rebaudiana) was formulated, and Group C was formulated according to the treatment principle of "resolving phlegm and dampness, strengthening the spleen and promoting digestion" (6 g of Chenpi, 6 g of Fructus Mume, 10 g of Herba Dendrobii, 10 g of Semen Lablab Album, 15 g of Fructus Hordei Germinatus, 6 g of Fructus Crataegi, 15 g of Folium Microcos, 3 g of Stevia rebaudiana). All the above medicinal materials were purchased from Xingyuanchun.

[0050] 2. Experimental methods

[0051] (1) Preparation of traditional Chinese medicine decoction

[0052] 1) Cut the Chinese medicine decoction pieces of Group A and Group B into small pieces, add water according to the ratio of material to liquid of 1:3 (g / mL), and decoct for 30-40 min to obtain the medicinal liquid and the medicinal residues. Repeat the step of adding water for decoction to decoct the medicinal residues twice, combine the medicinal liquids, filter, and concentrate to 0.153 g / mL.

[0053] 2) Take the Chinese medicine decoction pieces of Group C and follow step 1), filter the medicinal liquid and concentrate it to the raw drug amount of 0.306 g / mL, and use it as the high-dose medicinal liquid. Then, perform gradient serial dilution to obtain 0.153 g / mL (medium-dose medicinal liquid) and 0.0765 g / mL (low-dose medicinal liquid).

[0054] (2) Establishment of animal model

[0055] After one week of adaptive feeding, all C57BL / 6J mice were randomly divided into 8 groups according to body weight, with 6 mice in each group; except for the 6 mice in the control group, the other groups were fed with a high-fat diet for 12 weeks.

[0056] (3) Experimental grouping and drug administration

[0057] Six mice were selected as the control group (normally fed mice with normal body weight), and the remaining 42 mice were randomly divided into the model group, positive drug (orlistat) group, A group, B group, low-dose C group, medium-dose C group, and high-dose C group, with 6 mice in each group. They were fed with high-fat diet during the drug administration period. The control group was not intervened, and the model group was given an equal amount of normal saline by gavage. The other groups were given corresponding drug intervention (12.42 mL of gavage per day) -1 kg -1 ·d -1 , among which the positive drug group: Orlistat 75mg -1 kg -1 ·d -1 ; Group A is equivalent to 1.90g of crude drug -1 kg -1 ·d -1 ; Group B is equivalent to 1.90g of crude drug -1 kg -1 ·d -1 ; Group C: Low dose group equivalent to 0.95g of crude drug -1 kg -1 ·d -1 , the medium dose group is equivalent to 1.90g of crude drug -1 kg -1 ·d -1 , the high dose group is equivalent to 3.80g of crude drug -1 kg -1 ·d -1 . Continuous administration for 12 weeks), once a day.

[0058] (4) Detection method

[0059] 1) General observation

[0060] The general condition of mice, including their mental state, food intake, water intake, urine output, feces output, body weight, body hair, and activity. After administration, the general symptoms were continuously observed to see if the animals showed any abnormal symptoms.

[0061] 2) Serum biochemical index determination

[0062] After the drug intervention, the blood of the mice was separated to obtain serum, and the levels of total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C) and liver function indicators alanine aminotransferase (ALT), aspartate aminotransferase (AST), and renal function indicators creatinine (Cr) and blood urea nitrogen (BUN) in the upper serum were tested.

[0063] 3) Determination of white fat content

[0064] After the drug intervention, the mice were anesthetized and killed, and the weights of inguinal white fat (iWAT), epididymal white fat (eWAT) and perirenal white fat (pWAT) were weighed and statistically analyzed.

[0065] 4) Pathological section staining

[0066] After the mice were killed, a portion of the liver and epididymal adipose tissue was cut, fixed with paraformaldehyde, dehydrated, and embedded. Tissue sections were cut and stained with HE. The fields of view of the liver HE-stained sections were randomly selected to evaluate the non-alcoholic fatty liver disease (NAFLD) score of the mouse liver. The total NAFLD score ranged from 0 to 12. The larger the number, the more severe the fatty degeneration. The diameter of the adipocytes was measured based on the HE staining of the epididymal adipose tissue.

[0067] (5) Statistical methods

[0068] Two independent sample t tests were used for animal experiments, and P < 0.05 indicated statistical significance.

[0069] 3. Results

[0070] (1) General observation

[0071] During the entire experiment, the mice in the control group moved freely, had normal diet and drinking water, had bright eyes, shiny fur, ruddy and shiny tails, gradually gained weight, had normal urine and feces output, had no symptoms of weight loss or abdominal distension, and were in good spirits. The mice in the model group had significantly increased food intake, water intake, and urine output. Their fur began to become fluffy, erect, messy, and dull, and they preferred to lie down and were averse to movement. They also had varying degrees of hair loss and weight gain. As shown in Table 1, after 12 weeks of drug administration, the mice in each group had the same amount of food intake as the modeling group, but their water intake increased, their spirits gradually improved, and their weight decreased. Figure 1As shown in the figure, after 12 weeks of high-fat diet feeding, the body weight of mice in the model group increased significantly. Compared with the model group, the body weight of mice in the high-dose group and the medium-dose group of the C group decreased significantly after administration (p<0.001). The B group and the low-dose group of the C group and the metformin group were compared with the model group (p<0.05), while the efficacy of the A group was the lowest. This shows that the B group and the C group can effectively improve obesity caused by high-fat diet feeding, and the role of the main drug tangerine peel is indispensable. At the same time, the efficacy of the C group is better, and there is an obvious dose effect.

[0072] Table 1 Effects of Chenpi Jianpi Qutan Recipe and its proposed recipe on diet and body weight of mice

[0073]

[0074] (2) Four blood lipid levels

[0075] The four blood lipids include total cholesterol, triglycerides, high-density lipoprotein and low-density lipoprotein, which are often used to assess the individual's lipid metabolism level. Figure 2 and Figure 3 As shown in the results, Chenpi Jianpi Qutan Recipe can significantly prevent the increase of total cholesterol and low-density lipoprotein levels in mice fed a high-fat diet, and the high-dose drug effect is better (p<0.001). From the results of each group of medication, the B group can reduce the low-density lipoprotein level of mice fed a high-fat diet, but both A and B can not improve the level of total cholesterol (p>0.05), indicating that Chenpi Jianpi Qutan Recipe has a significant effect on improving lipid metabolism and is better than the relevant proposed prescriptions.

[0076] Table 2 Effects of Chenpi Jianpi Qutan Recipe and its proposed recipe on the four blood lipid levels in mice

[0077]

[0078] (3) Impact of liver and kidney function indicators

[0079] See Table 3. Figures 4 to 7 The results of mouse liver and kidney function indicators showed that Chenpi Jianpi Qutan Recipe and the proposed recipes A and B could reduce the levels of alanine aminotransferase and aspartate aminotransferase in mice fed a high-fat diet (p<0.05), which means that the Chinese medicinal ingredients in the Chenpi Jianpi Qutan Recipe have a good liver-protecting effect and can improve fatty liver lesions caused by lipid metabolism disorders; there was no statistical difference in the changes in creatinine and urea nitrogen levels (p>0.05), indicating that the Chenpi Jianpi Qutan Recipe is more safe and has no effect on renal function.

[0080] Table 3 Effects of Chenpi Jianpi Qutan Recipe and its proposed recipe on liver and kidney function in mice

[0081]

[0082] (4) White fat content

[0083] After 12 weeks of administration, the content of white fat in mice is shown in Table 4. Figures 8-9 As shown: Compared with the model group, the inguinal white fat, epididymal white fat and perirenal white fat content of the mice treated with Chenpi Jianpi Qutan Recipe and Proposed Recipe B were maintained at a lower level (p<0.05); the statistical results of the total white fat content and white fat index of mice showed that Chenpi Jianpi Qutan Recipe could significantly reduce the white fat content of mice fed a high-fat diet, and there was a dose effect; the white fat content and white fat index of mice in the Proposed Recipe A group were not statistically different from those in the model group (p>0.05), while the white fat content and white fat index of the Proposed Recipe B group decreased (p<0.05). The results showed that Chenpi Jianpi Qutan Recipe and Proposed Recipe B could reduce the white fat content of mice fed a high-fat diet, and the effect of Chenpi Jianpi Qutan Recipe was more significant (p<0.001).

[0084] Table 4 Effects of Chenpi Jianpi Qutan Recipe and its proposed recipe on the content of various adipose tissues in mice

[0085]

[0086]

[0087] (5) Nonalcoholic fatty liver-like lesions and adipocyte morphology

[0088] 1) NAFLD scoring

[0089] Nonalcoholic fatty liver disease (NAFLD) is a metabolic stress-induced liver injury closely related to insulin resistance and is a common complication in obese patients. Fig.10 As shown in Table 5 and Fig.11 As shown in the figure, the NAFLD score of the liver of the model group mice was also significantly increased. However, compared with the model group, the medium-dose and high-dose groups of Chenpi Jianpi Qutan Recipe significantly improved liver fatty degeneration and reduced the NAFLD score (p < 0.05). However, neither the proposed recipe A nor the proposed recipe B could improve the fatty liver-like lesions of the high-fat diet mice, and the NAFLD score was not statistically different (p > 0.05).

[0090] Table 5 Effects of Chenpi Jianpi Qutan Recipe and its proposed recipe on non-alcoholic fatty liver-like lesions in mice

[0091]

[0092] 2) Fat cell diameter

[0093] Adipocytes are the main cells that make up adipose tissue and are specialized in storing fat as energy. The extent of obesity depends on the size of the fat droplets in each adipocyte. After feeding mice for 12 weeks, the diameter of epididymal white fat in each group of mice was measured. The results of HE staining are shown in Figure 2. Fig.12 As shown, the diameter of adipocytes in the high-fat diet model group increased significantly, indicating that a large number of lipid droplets were stored in the cells. Fig.13 The analysis results showed that compared with the model group, the diameter of the adipocytes of mice in the Chenpi Jianpi Qutan prescription and the proposed prescription B groups was significantly reduced (p<0.05), while there was no statistical difference in the adipocytes of mice in the proposed prescription A group (p<0.05).

[0094] Table 6 Effects of Chenpi Jianpi Qutan Recipe and its proposed recipe on the diameter of mouse adipocytes

[0095]

[0096]

[0097] 4. Conclusion

[0098] The experimental results show that the high-fat diet mouse model showed obvious weight gain, dyslipidemia, liver fatty lesions and other symptoms, and the quality of life of the mice decreased significantly. Chenpi Jianpi Qutan Recipe can improve the body weight, dyslipidemia, non-alcoholic fatty liver-like lesions and fat cell hypertrophy of mice on a high-fat diet, and its efficacy is better than that of the relevant proposed recipes. In addition, Chenpi Jianpi Qutan Recipe has a significant dose effect, and the efficacy of the high-dose group is significantly higher than that of the low-dose group.

[0099] The results showed that the water extract of Chenpi Jianpi Qutan recipe can improve the body weight, dyslipidemia, non-alcoholic fatty liver-like lesions and fat cell hypertrophy of mice fed a high-fat diet, and has a certain effect of protecting the liver. This provides a basic basis for the treatment of obesity with Chenpi Jianpi Qutan recipe, and Chenpi Jianpi Qutan recipe is expected to be developed into a new generation of drugs for the treatment of obesity.

[0100] Conclusion: After years of exploration, the inventors have discovered the potential value of Chenpi Jianpi Qutan Recipe in the treatment of obesity. The inventors selected simple obesity, which has a very high incidence rate, for animal experimental research. The results of the study suggest that the water extract of Chenpi Jianpi Qutan Recipe has a reliable therapeutic effect in the treatment of high-fat diet obese mice, and has the characteristics of high safety, which is worthy of further in-depth drug research and development.

[0101] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A Chinese medicine composition for treating obesity, characterized in that The invention comprises the following ingredients by weight: 4-8 parts of dried tangerine peel, 4-8 parts of black plum, 8-12 parts of dendrobium, 8-12 parts of white hyacinth bean, 13-17 parts of malt, 4-8 parts of hawthorn, 13-17 parts of buzia leaves and 1-5 parts of stevia.

2. The Chinese medicine composition for treating obesity according to claim 1, characterized in that The invention comprises the following ingredients by weight: 5-7 parts of dried tangerine peel, 5-7 parts of black plum, 9-11 parts of dendrobium, 9-11 parts of white hyacinth bean, 14-16 parts of malt, 5-7 parts of hawthorn, 14-16 parts of buzia leaves and 2-4 parts of stevia.

3. The Chinese medicine composition for treating obesity according to claim 1 or 2, characterized in that: The obesity described is simple obesity; The malt is roasted malt.

4. Use of the Chinese medicine composition for treating obesity according to any one of claims 1 to 3 in the preparation of a preparation for treating obesity.

5. A preparation for treating obesity, characterized in that The preparation is carried out by the following steps: extracting the Chinese medicine composition for treating obesity according to any one of claims 1 to 3, and preparing the desired dosage form with the obtained extract.

6. The preparation for treating obesity according to claim 5, characterized in that: The extraction includes water extraction and supercritical extraction.

7. The preparation for treating obesity according to claim 6, characterized in that: The water extraction steps are as follows: soaking the traditional Chinese medicine composition for treating obesity in water, followed by decocting, solid-liquid separation, obtaining a medicinal solution and a medicinal residue, repeatedly decocting the medicinal residue for more than 0 times, combining the obtained medicinal solutions, and obtaining an extract.

8. The preparation for treating obesity according to claim 7, characterized in that: The amount of water is calculated according to the ratio of the Chinese medicine composition for treating obesity: water = solid-liquid ratio of 1:2 to 1:15 (g:mL); The decoction time is 30 to 60 minutes; The amount of water used in the repeated decoction is calculated according to the ratio of the Chinese medicine composition for treating obesity: water = solid-liquid ratio of 1:2 to 1:15 (g:mL); The repeated decoction time is 30 to 60 minutes; The number of repeated decoctions is 1 to 3 times.

9. The preparation for treating obesity according to claim 5, characterized in that: The dosage form is decoction, pill, powder, paste, pill, granule, oral liquid, capsule, tablet or injection; The preparations include common preparations, sustained-release preparations, controlled-release preparations, targeted preparations and microparticle drug delivery systems.

10. The method for using the preparation for treating obesity according to claim 5, characterized in that The method comprises the following steps: taking the medicine twice a day, taking the medicine again after six hours after the first taking, and exercising moderately one hour after taking the medicine, until a slight sweat is desired.

Images